Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  panitumumab
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 82 for your search:
Start Over
PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20040249, NCT00115765
Topical Sunscreen in Preventing Skin Rash in Patients Receiving Drugs Such as Erlotinib or Cetuximab for Cancer
Phase: Phase III
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000492254, NCCTG-N05C4, N05C4, NCT00362986
Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20050181, NCT00339183
PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20050203, NCT00364013
Phase III Randomized Study of Irinotecan Hydrochloride With Versus Without Panitumumab or Cyclosporine in Patients With Fluorouracil-Resistant Advanced or Metastatic Colorectal Cancer. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.
Phase: Phase III
Type: Treatment
Status: Unknown
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: CTRU-PICCOLO-MO-05-7289, EUDRACT-2005-003492-20, CTAAC-CTRU-PICCOLO-MO-05-7289, AMGEN-CTRU-PICCOLO-MO-05-7289, EU-20647, NCT00389870
Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20050251, NCT00460265
Phase III Randomized Pilot Study of Neoadjuvant and Adjuvant Fluorouracil and Oxaliplatin With or Without Panitumumab in Patients With Resectable High-Risk Colon Cancer. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Unknown
Age: Any age
Sponsor: Other
Protocol IDs: BCTU-FOXTROT-001, BCTU-FOxTROT-001, ISCRTN 87163246, EUDRACT 2007-001987-55, EU-20830, MREC-07/S0703/57, UKCRN 3771, NCT00647530
Radiation Therapy and Cisplatin or Panitumumab in Treating Patients With Locally Advanced Stage III or Stage IV Head and Neck Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: HN6, CAN-NCIC-HN6, CDR0000630159, NCT00820248
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20080763, ASPECCT, 2009-010715-32, NCT01001377
Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer
Phase: Phase III
Type: Supportive care, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20100007, NCT01412957
Phase I/II Study of Panitumumab, Capecitabine and Oxaliplatin w EBRT for Esophageal Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 to 82
Sponsor: Other
Protocol IDs: Pro00002207, SPS 151596, NCT00578071
Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20060332, 2007-004722-25, NCT00630786
Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20060447, NCT00788957
New Individualized Therapy Trial for Metastatic Colorectal Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: CSTI571BUS278T, NCT00867334
Chemoradiation With Gemcitabine in Combination With Panitumumab for Patients With Locally Advanced Pancreatic Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 20080686, NCT01175733
Monoclonal Antibody Therapy in Treating Patients With Metastatic Colorectal Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000069368, UCLA-0112063, IMMUNEX-054-0005, NCI-G02-2073, NCT00039273
Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000269889, P30CA016042, UCLA-0206074, ABX-0301, NCT00054574
Phase II Randomized Study of Monoclonal Antibody ABX-EGF, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: UCLA-0304051, IMMUNEX-054.0004, ABX-0304, AMGEN-20025404, NCT00034346
ABX-EGF (a Monoclonal Antibody) Given to Patients With Prostate Cancer With or Without Tumor in Other Parts of the Body
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ABX-0310, ABX-EGF, NCT00061126
Phase II Study of Monoclonal Antibody ABX-EGF as Second-Line Treatment for Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: UCLA-0308088, IMMUNEX-054.0008, AMGEN-20025408, ABX-0308, NCT00079209
Phase II Study of Monoclonal Antibody ABX-EGF in Patients With Metastatic Colorectal Cancer That Failed Prior Chemotherapy Comprising Fluoropyrimidine, Irinotecan, and Oxaliplatin
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: UCLA-0402029-01, AMGEN-2003167, NCT00083616
Phase 2 Study of ABX-EGF (Panitumumab) in Japanese Subjects With M-colorectal Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20050216, NCT00327119
Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to Treatment
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20060277, NCT00411450
Phase 2, Open-label Trial of Skin Toxicity Treatment in mCRC Subjects Receiving Panitumumab + Irinotecan-based Therapy
Phase: Phase II
Type: Supportive care, Treatment
Status: Completed
Age: 18 to 90
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20050184, NCT00332163
Start Over